» Articles » PMID: 32046664

The S68G Polymorphism is a Compensatory Mutation Associated with the Drug Resistance Mutation K65R in CRF01_AE Strains

Overview
Journal BMC Infect Dis
Publisher Biomed Central
Date 2020 Feb 13
PMID 32046664
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The rate of S68G mutation in human immunodeficiency virus type 1 (HIV-1) reverse transcriptase has increased and is closely related to the K65R mutation among CRF01_AE-infected patients who failed treatment. We aimed to explore the temporal association of S68G and K65R mutations and disclose the role of the former on susceptibility to nucleotide/nucleoside reverse transcriptase inhibitor (NRTI) and viral replication with the K65R double mutations among CRF01_AE-infected patients who failed treatment.

Methods: The occurrence of S68G and K65R mutations was evaluated among HIV-1 of various subtypes in the global HIV Drug Resistance Database. The temporal association of S68G and K65R mutations was analyzed through next-generation sequencing in four CRF01_AE-infected patients who failed treatment with tenofovir/lamivudine/efavirenz. The impact of the S68G mutation on susceptibility to NRTI and replication fitness was analyzed using pseudovirus phenotypic resistance assays and growth competition assays, respectively.

Results: The frequency of the S68G mutation increased by 1.4-9.7% in almost all HIV subtypes and circulating recombinant forms in treatment-experienced patients, except subtype F. The S68G mutation often occurred in conjunction with the K65R mutation among RTI-treated patients, with frequencies ranging 21.1-61.7% in various subtypes. Next-generation sequencing revealed that the S68G mutation occurred following the K65R mutation in three of the four CRF01_AE-infected patients. In these three patients, there was no significant change detected in the half maximal inhibitory concentration for zidovudine, tenofovir, or lamivudine between the K65R and K65R/S68G mutations, as demonstrated by the phenotypic resistance assays. Virus stocks of the K65R and K65R/S68G mutations were mixed with 4:6, 1:1, and 9:1 and cultured for 13 days, the K65R/S68G mutants outgrew those of the K65R mutants irrespective of the input ratio.

Conclusions: S68G may be a natural polymorphism and compensatory mutation of K65R selected by NRTIs in the CRF01_AE strain of HIV-1. This mutation does not affect susceptibility to NRTI; however, it improves the replication fitness of K65R mutants. This study deciphers the role of the S68G mutation in the HIV reverse transcriptase of the CRF01_AE strain and provides new evidence for the interpretation of drug-resistant mutations in non-B subtypes of HIV-1.

Citing Articles

Distinct Clusters of HIV-1 CRF01_AE in Zhejiang, China: High-Risk Transmission Cluster 4 Requires Heightened Surveillance.

Dai B, Peng X, Sun J, Zhu X, Liu X, Xiong Y Infect Drug Resist. 2024; 17:4333-4342.

PMID: 39411499 PMC: 11476370. DOI: 10.2147/IDR.S480192.


The profile of HIV-1 drug resistance in Shanghai, China: a retrospective study from 2017 to 2021.

Zhang M, Ma Y, Wang G, Wang Z, Wang Q, Li X J Antimicrob Chemother. 2024; 79(3):526-530.

PMID: 38300833 PMC: 10904715. DOI: 10.1093/jac/dkad370.


HIV-1 Resistance to Islatravir/Tenofovir Combination Therapy in Wild-Type or NRTI-Resistant Strains of Diverse HIV-1 Subtypes.

Cilento M, Wen X, Reeve A, Ukah O, A Snyder A, Carrillo C Viruses. 2023; 15(10).

PMID: 37896768 PMC: 10612037. DOI: 10.3390/v15101990.


Artificial-Intelligence-Based Models Coupled with Correspondence Analysis Visualization on ART-Cases from Gombe State, Nigeria: A Comparative Study.

Bala K, Etikan I, Usman A, Abba S Life (Basel). 2023; 13(3).

PMID: 36983868 PMC: 10057492. DOI: 10.3390/life13030715.

References
1.
Garforth S, Domaoal R, Lwatula C, Landau M, Meyer A, Anderson K . K65R and K65A substitutions in HIV-1 reverse transcriptase enhance polymerase fidelity by decreasing both dNTP misinsertion and mispaired primer extension efficiencies. J Mol Biol. 2010; 401(1):33-44. PMC: 2925049. DOI: 10.1016/j.jmb.2010.06.001. View

2.
Gu Z, Arts E, Parniak M, Wainberg M . Mutated K65R recombinant reverse transcriptase of human immunodeficiency virus type 1 shows diminished chain termination in the presence of 2',3'-dideoxycytidine 5'-triphosphate and other drugs. Proc Natl Acad Sci U S A. 1995; 92(7):2760-4. PMC: 42298. DOI: 10.1073/pnas.92.7.2760. View

3.
Theys K, Deforche K, Vercauteren J, Libin P, van de Vijver D, Albert J . Treatment-associated polymorphisms in protease are significantly associated with higher viral load and lower CD4 count in newly diagnosed drug-naive HIV-1 infected patients. Retrovirology. 2012; 9:81. PMC: 3487874. DOI: 10.1186/1742-4690-9-81. View

4.
Gibson R, Schmotzer C, Quinones-Mateu M . Next-Generation Sequencing to Help Monitor Patients Infected with HIV: Ready for Clinical Use?. Curr Infect Dis Rep. 2014; 16(4):401. DOI: 10.1007/s11908-014-0401-5. View

5.
Petropoulos C, Parkin N, Limoli K, Lie Y, Wrin T, Huang W . A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob Agents Chemother. 2000; 44(4):920-8. PMC: 89793. DOI: 10.1128/AAC.44.4.920-928.2000. View